Illumina selected for Singapore genome study targeting 450,000 participants
Illumina has been selected to provide whole-genome sequencing for Singapore's SG-INSIGHT study. The project, part of Phase III of the National Precision Medicine programme, is expected to cover about 450,000 people, the company said in its 2 November release.

Edivro Company News · Original attributed summary. Source announcement: 2026-11-02.
Illumina has been selected to provide whole-genome sequencing for Singapore's SG-INSIGHT study. The project, part of Phase III of the National Precision Medicine programme, is expected to cover about 450,000 people, the company said in its 2 November release.
SG-INSIGHT will link genomic and health information to study disease and treatment responses. It extends the programme beyond earlier work focused on healthy volunteers, with the aim of informing how genetic screening might be introduced responsibly in public healthcare.
Illumina says selection followed an international competitive tender. Sequencing will take place at its Singapore genomics facility, which will seek the necessary accreditation. The announcement describes a planned evidence-building study; it does not establish improved patient outcomes.
What is SG-INSIGHT studying?
It will connect genomic and health data to examine disease and treatment responses and inform possible precision-healthcare approaches.
How large is the planned study?
Approximately 450,000 participants, described by Illumina as around one in ten Singapore residents.
Source: Official announcement.
Questions about this story
These answers summarise the article and refer to its original reporting period.
What is SG-INSIGHT studying?
It will connect genomic and health data to examine disease and treatment responses and inform possible precision-healthcare approaches.
How large is the planned study?
Approximately 450,000 participants, described by Illumina as around one in ten Singapore residents.
Publisher
Edivro Editorial

